Daltolizumab is an injectable liquid preparation whose specific dosage is adjusted according to different populations, premedication, the presence or absence of drug side effects, and the patient’s physical condition. Different population groups: The dosage of dalteplumab varies from person to person. For example, for adults, for weeks 1-8, 16mg/kg once a week; for weeks 9-24, the dosage is the same as before, and the frequency of use is adjusted to once every two weeks; from week 25 onwards, the dosage is changed to once every four weeks, and it needs to be adjusted accordingly depending on the different medicines used in combination. Pre-medication treatment: The use of this drug is prone to infusion-related reactions, which need to be treated with medication before use, such as dexamethasone, methylprednisolone and other corticosteroids. Side effects: This drug is mainly applied to myeloma disease, for anti-tumor drugs, it will produce a variety of adverse drug reactions, such as hematotoxicity, there will be myelosuppression, the level of the three lineage of blood cells decreased, or cardiovascular disease such as atrial fibrillation, or allergic reactions, immune system disorders, you can delay the use of the drug, or adjust the amount of dosage accordingly, depending on the condition of the specific dosage. Physical condition: This drug activates hepatitis B virus and affects liver and kidney function. If the patient has severe abnormalities in liver and kidney function, or has chronic viral hepatitis B and other diseases, the drug can be delayed or the dosage can be adjusted accordingly. To summarize, the dosage of this drug needs to be used in accordance with the doctor’s instructions, not self-medication.